One month after completion of radiation/ temozolomide (TMZ), patients started UCPvax vaccinations on days 1, 8, 15, 29, 36 and 43, then every two months until tumor progression. In this population of unmethylated MGMT GBM patients, UCPVax is highly immunogenic and provides an interesting OS rate. These data strongly support the completion of the second ongoing cohort, assessing UCPvax in combination with TMZ for GBM patients with methylated MGMT promoter status.
Combining anti-PD-1/PD-L1 therapy with an anti-telomerase vaccine gains serious consideration in HCC, in order to extend the clinical efficacy of anti-PD-1/PD-L1. Indeed, anti-cancer vaccines can induce tumor-specific T cell expansion and activation and therefore restore the cancer-immunity cycle in patients lacking pre-existing anti-tumor responses. Thus, there is a strong rational to combine immune checkpoint blockade therapy and anticancer vaccine (UCPVax) in order to activate antitumor T cell immunity and bypass the immunosuppression in the tumor microenvironment in HCC. This pivotal proof of concept study will evaluate the efficacy and safety of the combination of a CD4 Th1-inducer cancer vaccine derived from telomerase (UCPVax) and atezolizumab plus bevacizumab in unresectable HCC, as well as confirming their synergic mechanism, and settling the basis for a new combination for future clinical trials.
P2, N=56, Active, not recruiting, Centre Hospitalier Universitaire de Besancon | Recruiting --> Active, not recruiting | Trial completion date: May 2023 --> Dec 2024 | Trial primary completion date: Nov 2022 --> Dec 2023
over 1 year ago
Enrollment closed • Trial completion date • Trial primary completion date
This pivotal proof of concept study will evaluate the efficacy and safety of the combination of a telomerase-based T1 inducing vaccine (UCPVax) and an anti-PD-L1 (atezolizumab) immunotherapy in HPV cancers, as well as confirming their synergic mechanism, and settling the basis for a new combination for future clinical trials. https://www.clinicaltrials.gov/, identifier NCT03946358.
over 2 years ago
P2 data • Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
P1/2, N=54, Active, not recruiting, Centre Hospitalier Universitaire de Besancon | Recruiting --> Active, not recruiting | Trial completion date: Jun 2022 --> Dec 2023 | Trial primary completion date: Sep 2021 --> May 2022
over 2 years ago
Enrollment closed • Trial completion date • Trial primary completion date